These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10539393)
1. Challenges to the economic evaluation of new biotechnological interventions in healthcare. Mason J Pharmacoeconomics; 1999 Aug; 16(2):119-25. PubMed ID: 10539393 [TBL] [Abstract][Full Text] [Related]
2. Biotechnology: a special case for health technology assessment? Mason J; Drummond M Health Policy; 1997 Jul; 41(1):73-81. PubMed ID: 10169063 [TBL] [Abstract][Full Text] [Related]
3. The challenge of integrating monoclonal antibodies into the current healthcare system. Brixner DI; Bull SA Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294 [TBL] [Abstract][Full Text] [Related]
5. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant. Goa KL; Bryson HM Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867 [TBL] [Abstract][Full Text] [Related]
6. The evolution of biotechnology and its impact on health care. Evens R; Kaitin K Health Aff (Millwood); 2015 Feb; 34(2):210-9. PubMed ID: 25646100 [TBL] [Abstract][Full Text] [Related]
7. Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors. Drummond M; Menzin J; Oster G Pharmacoeconomics; 1994; 6 Suppl 2():18-26. PubMed ID: 10155592 [TBL] [Abstract][Full Text] [Related]
9. Construction Biotechnology: a new area of biotechnological research and applications. Stabnikov V; Ivanov V; Chu J World J Microbiol Biotechnol; 2015 Sep; 31(9):1303-14. PubMed ID: 26070432 [TBL] [Abstract][Full Text] [Related]
10. Development of health biotechnology in developing countries: can private-sector players be the prime movers? Abuduxike G; Aljunid SM Biotechnol Adv; 2012; 30(6):1589-601. PubMed ID: 22617902 [TBL] [Abstract][Full Text] [Related]
11. Product development plan for new vaccine technologies. Ellis RW Vaccine; 2001 Feb; 19(13-14):1559-66. PubMed ID: 11166875 [No Abstract] [Full Text] [Related]
13. Perspectives on high technologies for low-cost healthcare. Poon CC; Zhang YT IEEE Eng Med Biol Mag; 2008; 27(5):42-7. PubMed ID: 18799389 [No Abstract] [Full Text] [Related]
14. [The role of biotherapy in multiple myeloma]. Petrucci MT; Tafuri A; Mandelli F Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735 [TBL] [Abstract][Full Text] [Related]
15. Case studies on the use of biotechnologies and on biosafety provisions in four African countries. Black R; Fava F; Mattei N; Robert V; Seal S; Verdier V J Biotechnol; 2011 Dec; 156(4):370-81. PubMed ID: 21763362 [TBL] [Abstract][Full Text] [Related]
16. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes. Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204 [No Abstract] [Full Text] [Related]
17. Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Opportunities and Challenges. Lamsal R; Zwicker JD Appl Health Econ Health Policy; 2017 Dec; 15(6):763-772. PubMed ID: 28822113 [TBL] [Abstract][Full Text] [Related]
18. Purified protein products of rDNA technology expressed in animal cell culture. Lubiniecki AS; Lupker JH Biologicals; 1994 Jun; 22(2):161-9. PubMed ID: 7522477 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic marrow transplantation and the use of hematopoietic growth factors. Appelbaum FR Stem Cells; 1995 Jul; 13(4):344-50. PubMed ID: 7549892 [TBL] [Abstract][Full Text] [Related]
20. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success. Evens RP; Kaitin KI Clin Pharmacol Ther; 2014 May; 95(5):528-32. PubMed ID: 24448474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]